Heparin Sensitive and Resistant Vascular Smooth Muscle Cells: Biology and Role in Restenosis

References

• Casu B. Structure of heparin and heparin fragments. Ann. N.Y. Acad. Sci. 1989; 556: 1–17
   PubMed Web of Science ®Google Scholar
• Hascall V. C., Heinegard D. K., Wight T. N. Proteoglycans: metabolism and pathology. Cell Biology of Extracellular Matrix, E. B. Hay. Plenum Press, New York 1991; 149–172
   Google Scholar
• Lindahl U., Hook M. Glycosaminoglycans and their binding to biological macromolecules. Ann. Rev. Biochem. 1978; 47: 385–417
   PubMed Web of Science ®Google Scholar
• Lindahl U., Kusche M., Lidholt K., Oscarsson L. G. Biosynthesis of heparin and heparan sulfate. Ann. N.Y. Acad. Sci. 1989; 556: 36–50
   PubMed Web of Science ®Google Scholar
• Maccarana M., Casu B., Lindahl U. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J. Biol. Chem. 1993; 268: 23898–23905
   PubMed Web of Science ®Google Scholar
• Walker A., Turnbull J. E., Gallagher J. T. Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor. J. Biol. Chem. 1994; 269: 931–935
   PubMed Web of Science ®Google Scholar
• Parthasarathy N., Goldberg I. J., Sivaram P., Mulloy B., Flory D. M., Wagner W. D. Oligosaccharide sequences of endothelial cell surface heparan sulfate proteoglycan with affinity for lipoprotein lipase. J. Biol. Chem. 1994; 269: 22391–22396
   PubMed Web of Science ®Google Scholar
• David G. Integral membrane heparan sulfate proteoglycans. FASEB J. 1993; 7: 1023–1030
   PubMed Web of Science ®Google Scholar
• Jackson R. L., Busch S. J., Cardin A. D. Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol. Rev. 1991; 71: 481–539
   PubMed Web of Science ®Google Scholar
• Karnovsky M. J., Wright T. C., Jr., Castellot J. J., Jr., Chaoy J., Lormeau J. C., Petitou M. Heparin, heparan sulfate, smooth muscle cells, and atherosclerosis. Heparin and Related Polysaccharides Structure and Activities, B. Bolland. N.Y. Acad. Sci., New York 1989; vol. 556: 268–281
   Google Scholar
• Lippman M. M. Glycosaminoglycans and cell division. Epithelial Mensenchymal Interactions, R. Fleischmajer, R. E. Billngham. Williams & Wilkins, Baltimore 1968; 208–229
   Google Scholar
• Ross R., Glomset J. A. The pathogenesis of atherosclerosis: Parts I and II. New. Engl. J. Med. 1976; 295: 369–377, 420-425.
   PubMed Web of Science ®Google Scholar
• Clowes A. W., Karnovsky M. J. Suppression by heparin of smooth muscle proliferation in injured arteries. Nature 1977; 265: 625–626
   PubMed Web of Science ®Google Scholar
• Guyton J. R., Rosenberg R. D., Clowes A. W., Karnovsky M. J. Inhibition of rat arterial smooth muscle cell proliferation by heparin. Circ. Res. 1980; 46: 625–634
   PubMed Web of Science ®Google Scholar
• Castellot J. J., Jr., Addonizio M., Rosenberg R., Karnovsky M. J. Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle cell growth. J. Cell Biol. 1981; 90: 372–379
   PubMed Web of Science ®Google Scholar
• Castellot J. J., Jr., Beeler D. L., Rosenberg R. D., Karnovsky M. J. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. J. Cell. Physiol. 1984; 120: 315–320
   PubMed Web of Science ®Google Scholar
• Wright T. C., Castellot J. J., Jr., Petitou M., Lormeau J. C., Choay J., Karnovsky M. J. Structural determinants of heparin's growth inhibitory activity. J. Biol. Chem. 1989; 264: 1534–1542
   PubMed Web of Science ®Google Scholar
• Schmidt A., Yoshida K., Buddeck E. The antiproliferative activity of arterial heparan sulfate enriched with 2-O-Sulfated uronic acid residues. J. Biol. Chem. 1992; 267: 19242–19247
   PubMed Web of Science ®Google Scholar
• Fritze L. M., Reilly C. F., Rosenberg R. D. An antiproliferative heparan sulfate species produced by postcon-fluent smooth muscle cells. J. Cell Biol. 1985; 100: 1041–1049
   PubMed Web of Science ®Google Scholar
• Edwards J. J., Wagner W. D. Cell surface heparan sulfate proteoglycan and chondroitin sulfate proteoglycan of arterial smooth muscle cells. Am. J. Path. 1992; 140: 193–205
   PubMed Web of Science ®Google Scholar
• Lawler J., Slayter H. The release of heparin binding peptides from platelet thrombospondin by proteolytic action of thrombin, plasmin, and trypsin. Thromb. Res. 1981; 22: 267–279
   PubMed Web of Science ®Google Scholar
• Sakashita S., Engvall E., Ruoslahti E. Basement membrane glycoprotein laminin binds to heparin. FEBS Letters 1980; 116: 243–246
   PubMed Web of Science ®Google Scholar
• Keller K. M., Keller J. M., Kuhn K. The C-terminus of type 1 collagen is a major binding site for heparin. Biochem. Biophys. Acta. 1986; 882: 1–5
   PubMed Web of Science ®Google Scholar
• San Antonio J. D., Lander A. D., Karnovsky M. J., Slayter H. S. Mapping the heparin-binding sites on type I collagen monomers and fibrils. J. Cell Biol. 1994; 125: 1179–1188
   PubMed Web of Science ®Google Scholar
• San Antonio J. D., Karnovsky M. J., Gay S., Sanderson R. D., Lander A. D. Interactions of syndecan-1 and heparin with human collagens. Gycobiol. 1994; 4: 327–332
   PubMed Web of Science ®Google Scholar
• Lark M. W., Culp L. A. Multiple classes of heparan sulfate proteoglycans from fibroblast substratum adhesion sites, affinity fractionation on columns of platelet factor 4, plasma fibronectin and octyl-sepharose. J. Biol. Chem. 1984; 259: 6773–6782
   PubMed Web of Science ®Google Scholar
• Woods A., Couchman J. R., Johansson S., Hook M. Adhesion and cytoskeletal organization of fibroblasts in response to fibronectin fragments. EMBO J. 1986; 5: 665–670
   PubMed Web of Science ®Google Scholar
• Gill P. J., Silbert C. K., Silbert J. E. Effects of heparan sulfate removal on attachment of fibroblasts and endothelial cells. Biochem. 1986; 25: 405–410
   PubMed Web of Science ®Google Scholar
• Brennan M. J., Oldberg A., Hayman E. G., Ruoslathi E. Effect of a proteoglycan produced by rat tumor cells on their adhesion to fibronectin-collagen substrata. Cancer Res. 1983; 43: 4302–4307
   PubMed Web of Science ®Google Scholar
• San Antonio J. D., Lander A. D., Wright T. C., Karnovsky M. J. Heparin inhibits the attachment and growth of Balb c/3T3 fibroblasts on collagen substrata. J. Cell. Physiol 1992; 150: 8–16
   PubMed Web of Science ®Google Scholar
• Piepkorn M. W., Chapman D. L. Glycosamino-glycans and the substrate attachment of murine myeloma, 3T3, and cutaneous fibrosarcoma cells. Lab. Invest. 1985; 53: 22–29
   PubMed Web of Science ®Google Scholar
• O'Neill C., Jordan P., Ireland G. Evidence for two distinct mechanisms of anchorage stimulation in freshly explanted and 3T3 Swiss mouse fibroblasts. Cell 1986; 44: 489–496
   PubMed Web of Science ®Google Scholar
• Campisi J., Medrana E. E. Cell cycle perturbations in normal and transformed Fibroblasts caused by detachment from the substratum. J. Cell. Physiol. 1983; 114: 53–60
   PubMed Web of Science ®Google Scholar
• Liau G., Chan L. M. Regulation of extracellular matrix RNA levels in cultured smooth muscle cells. J. Biol. Chem. 1989; 264: 10315–10320
   PubMed Web of Science ®Google Scholar
• Brown C. C., Balian G. Effect of heparin on synthesis of short chain collagen by chondrocytes and smooth muscle cells. J. Cell Biol. 1987; 105: 1007–1012
   PubMed Web of Science ®Google Scholar
• Majack R. A., Bornstein P. Heparin regulates the collagen phenotype of vascular smooth muscle cells: induced synthesis of an Mr 60,000 collagen. J. Cell Biol. 1985; 100: 613–619
   PubMed Web of Science ®Google Scholar
• El Nabout R., Martin M., Remy J., Robert L., LaFuma C. Heparin fragments modulate the collagen phenotype of fibroblasts from radiation induced subcutaneous fibrosis. Exp. Molec. Path. 1989; 51: 111–122
   PubMed Web of Science ®Google Scholar
• Gavriel P., Kagan H. M. Inhibition by heparin of the oxidation of lysine in collagen by lysyl oxidase. Biochem. 1988; 27: 2811–2815
   PubMed Web of Science ®Google Scholar
• Majack R. A., Coates-Cook S., Bornstein P. Platelet-derived growth factor and heparin-like glycosamino-glycans regulate thrombospondin synthesis and deposition in the matrix by smooth muscle cells. J. Cell Biol. 1985; 101: 1059–1070
   PubMed Web of Science ®Google Scholar
• Majack R. A., Goodman L. V., Dixit V. M. Cell surface thrombospondin is functionally essential for vascular smooth muscle cell proliferation. J. Cell Biol. 1988; 106: 415–422
   PubMed Web of Science ®Google Scholar
• Wight T. Proteoglycans in pathological conditions: atherosclerosis. Fed. Proc 1985; 44: 381–385
   PubMedGoogle Scholar
• Wight T. Cell biology of arterial proteoglycans. Arterioscl. 1995; 9: 1–20
   Google Scholar
• Snow A. D., Bolender R. P., Wight T. N., Clowes A. W. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. Am. J. Path. 1990; 137: 313–330
   PubMed Web of Science ®Google Scholar
• Potter-Pergio S., Wight T. Heparin causes the accumulation of heparan sulfate in cultures of arterial smooth muscle cells. Arch. Biochem. Biophys. 1996; 336: 19–26
   PubMed Web of Science ®Google Scholar
• Castellot J. J., Jr., Wong K., Herman R. L., Hoover D. F., Albertini T. C., Wright T. C. Binding and internalization of heparin by vascular smooth muscle cells. J. Cell. Physiol. 1985; 124: 13–20
   PubMed Web of Science ®Google Scholar
• Stavenow L., Lindblad B., Xu C. B. Unfractionated heparin and low molecular weight heparin do not inhibit the growth of proliferating human arterial smooth muscle cells in culture. Eur. J. Vase. Endovasc. Surg. 1995; 10(2)215–219
   PubMed Web of Science ®Google Scholar
• Castellot J. J., Jr., Pukac L. A., Caleb B. L., Wright T. C., Karnovsky M. J. Heparin selectively inhibits a protein kinase C dependent mechanism of cell cycle progression in calf aortic smooth muscle cells. J. Cell Biol. 1989; 109: 3147–3156
   PubMed Web of Science ®Google Scholar
• Dahlberg C., Thompson B., Joseph P., Garg H., Spence C., Quinn D., Boventre J., Hales C. Differential effect of three commercial heparins on Na+/H+ exchange and growth of PASMC. Am. J. Physiol. 1996; 270: L260–L265
   PubMed Web of Science ®Google Scholar
• Pukac L., Carter J., Ottlinger M. E., Karnovsky M. J. Mechanisms of inhibition by heparin of PDGF stimulated MAP kinase activation in vascular smooth muscle cells. J. Cell. Physiol. 1997; 172: 69–78
   PubMed Web of Science ®Google Scholar
• Ottlinger M. E., Pukac L. A., Karnovsky M. J. Heparin inhibits mitogen-activated protein kinase activation in intact rat vascular smooth muscle cells. J. Biol. Chem. 1993; 268: 19173–19176
   PubMed Web of Science ®Google Scholar
• Pukac L. A., Ottlinger M. E., Karnovsky M. J. Heparin suppresses specific second messenger pathways for protooncogene expression in rat vascular smooth muscle cells. J. Biol. Chem. 1992; 267: 3707–3711
   PubMed Web of Science ®Google Scholar
• Wachi H., Seyama Y., Tajima S. Modulation of elastin expression by heparin is dependent on the growth condition of vascular smooth muscle cells: Up-regulation of elastin expression by heparin in the proliferating cells is mediated by the inhibition of protein kinase C activity. J. Biochem. 1995; 118(3)582–586
   PubMed Web of Science ®Google Scholar
• Herbert J. M., Clowes M., Lea H. J., Pascal M., Clowes A. W. Protein kinase C alpha expression is required for heparin inhibition of rat smooth muscle cell proliferation in vitro and in vivo. J. Biol. Chem. 1996; 271: 25928–25935
   PubMed Web of Science ®Google Scholar
• Pukac L. A., Castellot J. J., Wright T. C., Caleb B. L., Karnovsky M. J. Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells. Cell Reg. 1990; 1: 435–443
   PubMedGoogle Scholar
• Miralem T., Wang A., Whiteside C. I., Templeton D. M. Heparin inhibits mitogen-activated protein kinase-dependent and -independent c-fos induction in mesangial cells. J. Biol. Chem. 1996; 271(29)17100–17106
   PubMed Web of Science ®Google Scholar
• Reilly C., Kindy M., Brown K., Rosenberg R., Sonenshein G. Heparin prevents vascular smooth muscle cell progression through G, phase of the cell cycle. J. Biol. Chem. 1989; 264: 6990–6995
   PubMed Web of Science ®Google Scholar
• Clowes A. W. Regulation of smooth muscle cell function by heparin. J. Vase. Surg. 1992; 15: 911–913
   PubMedGoogle Scholar
• Fedarko N. S., Conrad H. E. A unique heparan sulfate in the nuclei of hepatocytes: structural changes with the growth state of the cells. J. Cell Biol. 1986; 102: 587–599
   PubMed Web of Science ®Google Scholar
• Busch S. J., Martin G. A., Barnhart R. L., Mano M., Cardin A. D., Jackson R. L. Trans-repressor activity of nuclear glycosaminoglycans of fos and jun/AP-1 oncoprotein-mediated transcription. J. Cell Biol. 1992; 116: 31–42
   PubMed Web of Science ®Google Scholar
• Castellot J. J., Jr., Cochran D., Karnovsky M. J. Effect of heparin on vascular smooth muscle cellsI. Cell metabolism. J. Cell. Physiol. 1985; 124: 21–28
   PubMed Web of Science ®Google Scholar
• Flint N., Cove F. L., Evans G. S. Heparin simulates the proliferation of intestinal epithelial cells in primary culture. J. Cell Sci. 1994; 107: 401–411
   PubMed Web of Science ®Google Scholar
• Groggel G. C., Marinides G. N., Hovingh P., Hamond E., Linker A. Inhibition of rat mesangial cell growth by heparan sulfate. Am. J. Physiol. 1990; F259–F265
   Google Scholar
• Kimura I., Nagaura T., Naitoh T., Kobayashi S., Kimura M. Heparin inhibits the progression phase of subcultured endothelial cell proliferation in rat aorta. Jpn. J. Pharm. 1992; 60(4)369–375
   PubMedGoogle Scholar
• Resink T. J., Scott-Burden T., Baur U., Burgin M., Buhler F. R. Decreased susceptibility of cultured smooth muscle cells from SHR rats to growth inhibition by heparin. 7. Cell. Physiol. 1989; 138: 137–144
   Web of Science ®Google Scholar
• Eccleston-Joyner C. A., Gray S. D. Arterial hypertrophy in the fetal and neonatal spontaneously hypertensive rat. Hypertension 1988; 12: 513–518
   PubMed Web of Science ®Google Scholar
• San Antonio J. D., Karnovsky M. J., Ottlinger M. E., Schillig R., Pukac L. A. Isolation of heparin-insensitive aortic smooth muscle cells. Arterioscl. Thromb. 1993; 13: 748–757
   PubMedGoogle Scholar
• Barzu T., Herbert J. M., Desmouliere A., Carayon P., Pascal M. Characterization of rat aortic smooth muscle cells resistant to the antiproliferative activity of heparin following long-term heparin treatment. J. Cell. Physiol. 1994; 160: 239–248
   PubMed Web of Science ®Google Scholar
• Conroy S., Hart C., Perez-Reyes N., Giachelli C., Schwartz S., McDougall J. Characterization of human aortic smooth muscle cells expressing HPV16 E6 and E7 open reading frames. Am. J. Path. 1995; 147: 753–762
   PubMed Web of Science ®Google Scholar
• Reilly C. Rat vascular smooth muscle cells immortalized with SV40 large T antigen possess defined smooth muscle cell characteristics including growth inhibition by heparin. J. Cell. Physiol. 1990; 142: 342–351
   PubMed Web of Science ®Google Scholar
• Bennett M. R., Evan G. I., Newby A. C. Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of vascular smooth muscle cells by serum reduction, interferon-g, heparin, and cyclic nucleotide analogues and induces apoptosis. Circ. Res. 1994; 74: 525–536
   PubMed Web of Science ®Google Scholar
• Caleb B. L., Hardenbrook M., Cherington V., Castellot J. J., Jr. Isolation of vascular smooth muscle cell cultures with altered responsiveness to the antiproliferative effect of heparin. J. Cell. Physiol. 1996; 167: 185–195
   PubMed Web of Science ®Google Scholar
• Bennett M. R., Littlewood T., Hancock D., Evan G. I., Newby A. C. Down-regulation of the c-myc proto-oncogene in inhibition of vascular smooth muscle cell proliferation: A signal for growth arrest?. Biochem. J. 1994; 302: 710–708
   Google Scholar
• Fager G., Hansson G. K., Ottosson P., Dahllof B., Bondjers G. Human arterial smooth muscle cells in culture. Effects of platelet-derived growth factor and heparin on growth in vitro. Exp. Cell Res. 1988; 176: 319–335
   PubMed Web of Science ®Google Scholar
• Caplice N. M., West M. J., Campbell G. R., Campbell J. Inhibition of human vascular smooth muscle cell growth by heparin. The Lancet 1994; 344: 97–98
   PubMed Web of Science ®Google Scholar
• Stöhr S., Meyer T., Smolenski A., Kreuzer H., Buchwald A. B. Effects of heparin on aortic versus venous smooth muscle cells: similar binding with different rates of [3H]thymidine incorporation. J. Cardiovasc. Pharm. 1995; 25: 782–788
   PubMed Web of Science ®Google Scholar
• Chan P., Patel M., Betteridge L., Munro E., Schachter M., Wolfe J., Sever P. Abnormal growth regulation of vascular smooth muscle cells by heparin in patients with restenosis. The Lancet 1993; 341: 341–342
   PubMed Web of Science ®Google Scholar
• Chan P. Cell biology of human vascular smooth muscle. Ann. R. Coll. Surg. Engl. 1994; 76: 298–303
   PubMed Web of Science ®Google Scholar
• Refson J. S., Schachter M., Patel M. K., Chan P., Wolfe J. H. N., Sever P. Correlation of heparin binding with responsiveness in human vascular smooth muscle cells. Biochem. Soc. Trans. 1995; 23: 172S
   PubMed Web of Science ®Google Scholar
• Barzu T., Pascal M., Maman M., Roque C., LaFont F., Rousselet A. Entry and distribution of fluorescent antiproliferative heparin derivatives into rat vascular smooth muscle cells: Comparison between heparin-sensitive and heparin-resistant cultures. J. Cell. Physiol. 1996; 167: 8–21
   PubMed Web of Science ®Google Scholar
• Letoumeur D., Caleb B. L., Castellot J. J., Jr. Heparin binding, internalization, and metabolism in vascular smooth muscle cells:I. Upregulation of heparin binding correlates with antiproliferative activity. J. Cell. Physiol. 1995; 165: 676–686
   PubMed Web of Science ®Google Scholar
• Letoumeur D., Caleb B. L., Castellot J. J., Jr. Heparin binding, internalization, and metabolism in vascular smooth muscle cells: II. Degradation and secretion in sensitive and resistant cells. J. Cell. Physiol. 1995; 165: 687–695
   PubMed Web of Science ®Google Scholar
• Sartore S., Scatena M., Chiavegato A., Faggin E., Giuriato L., Pauletto P. Myosin isoform expression in smooth muscle cells during physiological and pathological vascular remodeling. J. Vasc. Res. 1994; 31: 61–81
   PubMed Web of Science ®Google Scholar
• Dartsch P. C., Voisard R., Bauriedel G., Hofling B., Betz E. Growth characteristics and cytoskeletal organization of cultured smooth muscle cells from human primary, stenosing and restenosing lesions. Arterioscl. 1990; 10: 62–75
   PubMedGoogle Scholar
• Schwartz S. M., Foy L., Bowen-Pope D. F., Ross R. Derivation and properties of platelet-derived growth factor-independent rat smooth muscle cells. Am. J. Path. 1990; 136: 1417–1428
   PubMed Web of Science ®Google Scholar
• Blaes N., Bourdillon M. C., Lamaziere J. M. D., Michaille J. J., Anduiar M., Covacho C. Isolation of two morphologically distinct cell lines from rat arterial smooth muscle expressing high tumorigenic potentials. In Vitro Cell Dev. Biol. 1991; 27A: 725–734
   PubMedGoogle Scholar
• Bondjers G., Glukhova M., Hansson G. K., Postnov Y. V., Reidy M. A., Schwartz S. M. Hypertension and atherosclerosis. Cause and effect, or two effects with one unknown cause?. Circ. 1991; 84: VI-2–VI-16
   Web of Science ®Google Scholar
• Desmouliere A., Rubbia-Brandt L., Grau G., Gabbiani G. Heparin induces alpha-smooth muscle actin expression in cultured fibroblasts and in granulation tissue myofibroblasts. Lab. Invest. 1992; 67(6)716–726
   PubMed Web of Science ®Google Scholar
• Gibbons G. H., Dzau V. J. Molecular therapies for vascular diseases. Science 1996; 212: 689–693
   Google Scholar
• Davies M. G., Hagen P. O. Pathobiology of inti-mal hyperplasia. Brit. J. Surg. 1994; 81: 1254–1269
   PubMed Web of Science ®Google Scholar
• Ellis S. G., Roubin G. S., Wilentz J., Douglas J. S., King S. B. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am. Heart J. 1989; 117: 777–782
   PubMed Web of Science ®Google Scholar
• Brack M. J., Ray S., Chauhan A., Fox J., Hubner P. J. B., Schofield P., Harley A., Gershlick A. H. The subcutaneous heparin and angioplasty restenosis prevention (SHARP) trial. Return of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome. J. Am. Coll. Cardio. 1995; 26(4)947–954
   PubMed Web of Science ®Google Scholar
• Lehmann K. G., Doria R. J., Feuer J. M., Hall P. X., Hoang D. T. Paradoxical increase in restenosis rate with chronic heparin use: final results of a randomized trial. J. Am. Coll. Cardiol. 1991; 17: 181A
   Google Scholar
• Boneau B., Dol F., Caranobe C., Sie P., Houin G. Pharmacokinetics of heparin and related polysaccharides. Ann. N. Y. Acad. Sci. 1989; 556: 282–291
   PubMed Web of Science ®Google Scholar
• Edelman E., Karnovsky M. J. Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circ 1994; 89: 770–776
   PubMed Web of Science ®Google Scholar
• Hajjar D. P. Viral pathogenesis of atherosclerosis. Am. J. Path. 1991; 39: 1195–1211
   Google Scholar
• Koyama H., Reidy M. A. Reinjury of arterial lesions induces intimal smooth muscle cell replication that is not controlled by fibroblast growth factor 2. Circ. Res. 1997; 80: 408–417
   PubMed Web of Science ®Google Scholar